Skip to content

Getting Vertex Pharmaceuticals’ Orphan Drug Kalydeco (Ivacaftor) To The UK Continues (October 9, 2012 Update)

October 9, 2012

       Getting Vertex Pharmaceuticals’ orphan drug Kalydeco (Ivacaftor) to the UK is continuing. This is the latest update as of October 9, 2012. 

       The Cystic Fibrosis (CF) Trust UK started an October 4, 2012 “Campaign for Kalydeco” along with the CF Trust UK  iPetition Campaign for Kalydeco. 

       The Clinical Priorities Advisory Group (CPAG) Meeting on Kalydeco (set up by the NHS in England) is held on September 25, 2012. 

        On October 9, 2012, CPAG publishes the minutes of this meeting.  Per the October 9, 2012 CF Trust Press Release : 

  1. “CPAG head that Kalydeco is a significant new step in managing cystic fibrosis” & “provides both long-term quality of life & survival benefit to patients”
  2. “Key message from this meeting was that there was support for the clinical effectiveness of the drug & cost effectiveness evaluation was next stage of the process”
  3. “The group would reconvene in 4 weeks’ time to undertake the next stage of the process, focusing on cost effectiveness”.

Copyright © 2012-2013, Ann-Teresa Cusenza and Orphan Druganaut Blog.  All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: